Myopia (short-sightedness) is a condition where distant objects look blurred while near objects stay clear. In most children it develops because the eyeball grows too long from front to back, so light focuses just in front of the retina instead of on it. This is the key point that explains everything else: myopia is not simply a need for glasses, it reflects a structural change in the size of the eye (axial elongation).

Why it matters beyond blur: the longer an eye becomes, the higher the lifetime risk of serious eye disease, including myopic maculopathy, retinal detachment, glaucoma, and earlier cataract. These risks rise as myopia increases, and there is no level of myopia that is completely free of risk. Myopia that starts in childhood usually progresses for several years, so a child with early onset and fast progression is the one most likely to reach high myopia as an adult. The aim of modern myopia control is therefore to limit how much and how long the eye grows, not just to clear the vision.

Common risk factors for developing or progressing myopia:

• One or both parents being short-sighted (family predisposition)

• Onset at a young age, and rapid progression in the first year or two

• East Asian ethnicity (higher prevalence and faster progression on average)

• Large amounts of sustained near work — reading, study, screens

• Limited time spent outdoors

• Urban living and high educational pressure

A child can have several of these and never become highly myopic, or have few and progress quickly. Risk factors raise the odds; they do not decide the outcome.

Atropine is an eye drop used at low concentrations (commonly 0.01% to 0.05%) to slow myopia progression, usually instilled once at night.

How it works. The mechanism is not fully understood. Although atropine relaxes the eye's focusing and enlarges the pupil, its myopia-control effect appears to come from its action on receptors in the retina and sclera that influence eye-growth signalling, rather than from changing how the eye focuses. In other words, it seems to slow axial elongation through a biochemical pathway, not an optical one.

Dose matters. Research (notably the LAMP studies) shows higher concentrations such as 0.05% slow progression more, but also cause more side effects and a stronger rebound — faster progression — when stopped. Lower concentrations such as 0.01% have fewer side effects but a more modest and less consistent effect. Choosing a concentration is a balance, individualised to the child.

Strengths:

• Simple to use — one drop at night — and not dependent on a child wearing a device correctly all day

• Can be combined with optical methods (see Combination Therapy)

• Generally well tolerated at low concentrations

Limitations and risks:

• It does not correct vision; the child still needs glasses or contact lenses to see clearly

• Higher concentrations can cause light sensitivity (from the larger pupil) and blurred near vision

• Rebound progression can follow stopping treatment, particularly at higher doses, so weaning is planned carefully

• In Australia, low-dose atropine for this purpose is generally compounded and prescribed off-label; quality and supply depend on the compounding pharmacy

• Prevention trials have been mixed: in children who are not yet myopic, very low-dose atropine has not reliably prevented myopia from starting, even though it can help slow progression once myopia is present

Optical myopia control changes the way light is focused across the whole retina, not just at its centre.

The peripheral defocus idea. Ordinary single-vision glasses and contact lenses are designed to focus light sharply at the centre of the retina. But because of the eye's shape, they often leave light in the peripheral retina focused behind it — a state called relative peripheral hyperopic defocus. The leading theory is that this "focus behind the retina" acts as a growth signal, encouraging the eye to keep elongating to reach it. Myopia-control optics are designed to remove that signal and instead place some light in front of the peripheral retina (myopic defocus), which appears to slow elongation.

Several designs use this principle:

• Myopia-control spectacle lenses — lenses with many small treatment zones or segments (such as DIMS and HAL designs) that keep central vision clear while building a peripheral myopic-defocus treatment into the lens.

• Soft myopia-control contact lenses — including dual-focus daily disposables such as MiSight, worn during the day.

• Orthokeratology (Ortho-K) — rigid lenses worn overnight that gently reshape the front surface of the cornea, giving clear unaided vision through the day and creating peripheral myopic defocus as a by-product. Ortho-K also removes the need for daytime glasses or lenses.

Risks and limitations:

• Spectacle and soft-lens designs rely on consistent, near full-time wear; part-time wear reduces the benefit.

• All contact lenses, including Ortho-K, carry a small but real risk of corneal infection, which increases with poor hygiene or sleeping in lenses not designed for it. Ortho-K in particular requires careful cleaning, regular review, and prompt attention to any red or painful eye.

• The effect is to slow progression, not stop it, and results vary between children.

RLRL involves looking into a desktop device that emits low-level red light (typically a laser at around 650 nm) for about three minutes, twice a day, on most days of the week.

Efficacy. In short-term clinical trials, mostly twelve months, and mostly from China. RLRL has produced some of the largest reductions in eye growth reported for any single myopia-control method, along with thickening of the choroid (a layer behind the retina). On the efficacy data alone, the results look striking.

Safety - a reassuring short-term record, with genuine long-term questions. The clinical safety record so far is encouraging. A 2024 systematic review covering around twenty studies and more than two thousand children found no cases of permanent vision loss or lasting structural damage, with side effects uncommon and usually limited to a brief afterimage that cleared within minutes. The reports of macular (central retinal) changes that have appeared - almost all from China, where the therapy is most widely used - have been isolated, and the affected children have recovered.

What keeps RLRL in the "emerging" rather than "established" category is not those cases, but what is still unknown:

• Long-term safety data simply do not exist yet. Most studies run only a year or two, and the therapy is too new to know what many years of use would do.

• A 2025 study using specialised retinal imaging found reduced cone (photoreceptor) density near the central fovea in some long-term users. It was retrospective, could not prove cause, and has not yet been confirmed by other research, but the authors themselves called for closer safety study, so it is not something to wave away.

• A 2026 laboratory analysis found that two laser-based devices reached recognised retinal-exposure limits within seconds, well short of the three-minute treatment, while a non-laser LED device stayed comfortably within limits. This was a worst-case bench calculation rather than a measurement in living eyes, and it sits in tension with the low rate of real-world harm - but it suggests the specific device, and laser versus LED, may matter a great deal.

Why China tightened its rules. It is worth understanding the regulatory story, because it is easy to misread. Under the previous system, around twenty companies had brought devices to market under weak, province-by-province oversight with no standardised proof of safety or efficacy. In 2024 the national regulator reclassified RLRL devices as high-risk, requiring far more rigorous national approval, and the 2025 national myopia guidelines did not list RLRL among their preferred options, favouring orthokeratology and low-dose atropine. The change was driven as much by the rapid spread of inadequately validated devices and unsupported marketing claims as by the open safety questions above.

The honest summary. RLRL is one of the more effective options on paper, and its short-term clinical safety record is reassuring. What is not yet known is how it behaves over many years, and outcomes likely depend heavily on the particular device. On that basis it is reasonable to treat RLRL as a promising but still-emerging therapy, and to weigh it alongside options that have longer safety track records.

How the two eyes work together at near - the accuracy of focusing and the alignment of the eyes - may influence how myopia behaves. When the eyes consistently under-focus at near (accommodative lag), or sit in certain alignment patterns, the resulting blur or strain is thought to act as an additional growth signal that can speed progression in some children. An undetected or poorly managed binocular vision problem can therefore work against myopia control. It may also contribute to one eye progressing faster than the other, producing an anisometropic shift (a growing difference in prescription between the two eyes). Assessing binocular vision is part of a thorough myopia assessment, not an optional extra.

For a child who keeps progressing despite a single treatment, combining two methods that work in different ways can add benefit.

The best-studied combination is low-dose atropine plus orthokeratology. Randomised trials have shown the combination slows eye growth more than Ortho-K alone - for example, one two-year trial found roughly 0.11 mm less axial growth over two years with the combination, with the advantage clearest in children with lower starting prescriptions. A shorter trial found a similar pattern, with most of the added benefit appearing in the first few months. Combining atropine with myopia-control spectacles or soft contact lenses has also shown promise, particularly in the youngest children.

The realistic picture: the added benefit is usually modest rather than dramatic, it is not guaranteed for every child, and it is generally reserved for faster progressors who need more than one approach can give alone. Combining treatments also means more cost and more to manage, so it is a considered decision rather than a default.

• "Under-correcting with weaker glasses slows myopia." Not true, and likely the opposite. Deliberately leaving a child under-corrected has been shown to slightly speed progression. Children should be fully corrected.

• "Sunlight and outdoor time help." Largely true, with one caveat (see The Power of Outdoor Time). Time outdoors is one of the few well-evidenced ways to reduce the chance of myopia starting.

• "Reading in dim light or sitting too close ruins your eyes." A partial truth at most. Prolonged, very close near work is associated with myopia, but a single habit such as dim-light reading is not a proven cause of permanent damage.

• "Diet or eye vitamins can fix myopia." Not supported. No food or supplement has been shown to prevent or reverse axial myopia.

• "It's all genetic, so nothing can be done." Not true. Family history is a real risk factor, but environment and behaviour clearly matter, and proven treatments can slow progression regardless of family history.

• "Myopia is just a glasses problem that stops in adulthood." Misleading. Myopia reflects eye growth and carries long-term eye-health risks, which is the entire reason for controlling it early.

Of everything in the myopia toolkit, time outdoors has some of the most consistent evidence - but it is important to be precise about what it actually does.

The research verdict. Spending more time outdoors clearly reduces the chance of a child developing myopia in the first place. Large pooled analyses show a dose-response relationship: increasing from around 3.5 hours a week to roughly 7, 16, and 27 hours a week has been linked to progressively lower odds of myopia onset - very roughly a 20%, 50%, and 70% reduction in risk. Commonly cited targets are about two hours a day, or 10 to 14 hours a week.

Once a child is already myopic, the evidence that extra outdoor time slows further progression is weak. Outdoor time is mainly a tool for prevention and delay; it does not replace myopia-control methods in a child who is already short-sighted. Why it helps is not fully settled, but bright outdoor light, and the dopamine it triggers in the retina, is the leading explanation.

These sound similar but target different points in the story, and the field's emphasis has been shifting.

• Myopia control means slowing progression in a child who is already myopic.

• Myopia prevention (or delay) means stopping or postponing myopia from starting in a child who is at risk but not yet short-sighted.

The shift. For years the focus was almost entirely on control. More recently, expert consensus - including the International Myopia Institute's 2025 update - has moved toward proactive, earlier intervention, treating prevention and delay as genuinely valuable goals. A major driver is the finding that delaying onset is highly leveraged: each year that onset is pushed back is estimated to be worth roughly two to three years of progression treatment later, because earlier-onset myopia tends to end up more severe. This has brought new attention to "pre-myopia," and to tracking a child's hyperopic reserve (the buffer of long-sightedness that young children normally have before they tip into myopia).

The honest balance. The evidence for prevention is younger and less settled than for control. Outdoor time has the strongest prevention evidence; low-dose atropine, RLRL, and newer spectacle designs are being studied for delaying onset, with mixed results so far. And because not every at-risk child will become myopic, preventive treatment means accepting that some children would have been fine without it, so it is weighed against each child's individual risk rather than applied to everyone.

Myopia control is an ongoing process, not a one-off fitting, and measuring progress objectively is central to it.

What we track:

• Axial length: the front-to-back length of the eye, measured with optical biometry. This is the most important number, because it reflects the actual eye growth that drives long-term risk, and it is compared against age-based growth charts.

• Refraction: the prescription, often measured in children under cycloplegia (drops that relax focusing) for accuracy.

• Eye health: and, where relevant, the fit and effect of lenses or drops.

What to expect:

• Reviews are typically about every six months, and sometimes more often early on.

• Success means slowing growth toward an age-appropriate range, not necessarily stopping it completely. A treatment can be working well even if a small amount of progression continues.

• Plans are adjusted over time. A child who keeps progressing may have their approach changed or combined, and treatment is usually continued until eye growth naturally settles in the later teens.

• Reporting any change between visits — blur, eye discomfort, or redness, especially with contact lenses or Ortho-K - is part of keeping treatment both effective and safe.